Literature DB >> 30137413

DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.

Shanshan Li1, Chu Xu1, Yinkun Fu1, Pin-Ji Lei2, Yanhua Yao1, Wanli Yang1, Ying Zhang3, Michael P Washburn3,4, Laurence Florens3, Manish Jaiswal5, Min Wu2, Man Mohan1.   

Abstract

DYRK1A, dual-specificity tyrosine phosphorylation-regulated kinase 1A, which is linked to mental retardation and microcephaly, is a member of the CMGC group of kinases. It has both cytoplasmic and nuclear functions, however, molecular mechanisms of how DYRK1A regulates gene expression is not well understood. Here, we identify two histone acetyltransferases, p300 and CBP, as interaction partners of DYRK1A through a proteomics study. We show that overexpression of DYKR1A causes hyperphosphorylation of p300 and CBP. Using genome-wide location (ChIP-sequencing) analysis of DYRK1A, we show that most of the DYRK1A peaks co-localize with p300 and CBP, at enhancers or near the transcription start sites (TSS). Modulation of DYRK1A, by shRNA mediated reduction or transfection mediated overexpression, leads to alteration of expression of downstream located genes. We show that the knockdown of DYRK1A results in a significant loss of H3K27acetylation at these enhancers, suggesting that DYRK1A modulates the activity of p300/CBP at these enhancers. We propose that DYRK1A functions in enhancer regulation by interacting with p300/CBP and modulating their activity. Overall, DYRK1A function in the regulation of enhancer activity provides a new mechanistic understanding of DYRK1A mediated regulation of gene expression, which may help in better understanding of the roles of DYRK1A in human pathologies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30137413      PMCID: PMC6265467          DOI: 10.1093/nar/gky754

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  44 in total

1.  Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins.

Authors:  Ying Zhang; Zhihui Wen; Michael P Washburn; Laurence Florens
Journal:  Anal Chem       Date:  2010-03-15       Impact factor: 6.986

2.  Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A.

Authors:  S Ait-Si-Ali; S Ramirez; F X Barre; F Dkhissi; L Magnaghi-Jaulin; J A Girault; P Robin; M Knibiehler; L L Pritchard; B Ducommun; D Trouche; A Harel-Bellan
Journal:  Nature       Date:  1998-11-12       Impact factor: 49.962

3.  Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling.

Authors:  Barbara Hämmerle; Edgar Ulin; Jordi Guimera; Walter Becker; François Guillemot; Francisco J Tejedor
Journal:  Development       Date:  2011-06       Impact factor: 6.868

4.  Riquiqui and minibrain are regulators of the hippo pathway downstream of Dachsous.

Authors:  Joffrey L Degoutin; Claire C Milton; Eefang Yu; Marla Tipping; Floris Bosveld; Liu Yang; Yohanns Bellaiche; Alexey Veraksa; Kieran F Harvey
Journal:  Nat Cell Biol       Date:  2013-08-18       Impact factor: 28.824

Review 5.  Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.

Authors:  L J Kay; T K Smulders-Srinivasan; M Soundararajan
Journal:  Adv Protein Chem Struct Biol       Date:  2016-08-09       Impact factor: 3.507

Review 6.  CBP and p300: HATs for different occasions.

Authors:  Eric Kalkhoven
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

7.  Phosphorylation of p300 increases its protein degradation to enhance the lung cancer progression.

Authors:  Shao-An Wang; Chia-Yang Hung; Jian-Ying Chuang; Wen-Chang Chang; Tsung-I Hsu; Jan-Jong Hung
Journal:  Biochim Biophys Acta       Date:  2014-02-11

8.  Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.

Authors:  Qiang Liu; Na Liu; Shaolei Zang; Heng Liu; Pin Wang; Chunyan Ji; Xiulian Sun
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 9.  DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.

Authors:  P Fernández-Martínez; C Zahonero; P Sánchez-Gómez
Journal:  Mol Cell Oncol       Date:  2015-01-30

10.  The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2.

Authors:  Florian Glenewinkel; Michael J Cohen; Cason R King; Sophie Kaspar; Simone Bamberg-Lemper; Joe S Mymryk; Walter Becker
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

View more
  10 in total

Review 1.  Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.

Authors:  Qingjuan Chen; Binhui Yang; Xiaochen Liu; Xu D Zhang; Lirong Zhang; Tao Liu
Journal:  Theranostics       Date:  2022-06-21       Impact factor: 11.600

Review 2.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

Review 3.  DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Authors:  Amina Jamal Laham; Maha Saber-Ayad; Raafat El-Awady
Journal:  Cell Mol Life Sci       Date:  2020-09-01       Impact factor: 9.261

4.  Systematic phenomics analysis of autism-associated genes reveals parallel networks underlying reversible impairments in habituation.

Authors:  Troy A McDiarmid; Manuel Belmadani; Joseph Liang; Fabian Meili; Eleanor A Mathews; Gregory P Mullen; Ardalan Hendi; Wan-Rong Wong; James B Rand; Kota Mizumoto; Kurt Haas; Paul Pavlidis; Catharine H Rankin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

5.  Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.

Authors:  Jérémie Courraud; Eric Chater-Diehl; Benjamin Durand; Marie Vincent; Maria Del Mar Muniz Moreno; Imene Boujelbene; Nathalie Drouot; Loréline Genschik; Elise Schaefer; Mathilde Nizon; Bénédicte Gerard; Marc Abramowicz; Benjamin Cogné; Lucas Bronicki; Lydie Burglen; Magalie Barth; Perrine Charles; Estelle Colin; Christine Coubes; Albert David; Bruno Delobel; Florence Demurger; Sandrine Passemard; Anne-Sophie Denommé; Laurence Faivre; Claire Feger; Mélanie Fradin; Christine Francannet; David Genevieve; Alice Goldenberg; Anne-Marie Guerrot; Bertrand Isidor; Katrine M Johannesen; Boris Keren; Maria Kibæk; Paul Kuentz; Michèle Mathieu-Dramard; Bénédicte Demeer; Julia Metreau; Rikke Steensbjerre Møller; Sébastien Moutton; Laurent Pasquier; Kristina Pilekær Sørensen; Laurence Perrin; Mathilde Renaud; Pascale Saugier; Marlène Rio; Joane Svane; Julien Thevenon; Frédéric Tran Mau Them; Cathrine Elisabeth Tronhjem; Antonio Vitobello; Valérie Layet; Stéphane Auvin; Khaoula Khachnaoui; Marie-Christine Birling; Séverine Drunat; Allan Bayat; Christèle Dubourg; Salima El Chehadeh; Christina Fagerberg; Cyril Mignot; Michel Guipponi; Thierry Bienvenu; Yann Herault; Julie Thompson; Marjolaine Willems; Jean-Louis Mandel; Rosanna Weksberg; Amélie Piton
Journal:  Genet Med       Date:  2021-08-03       Impact factor: 8.822

6.  DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.

Authors:  Mina Yousefelahiyeh; Jingyi Xu; Estibaliz Alvarado; Yang Yu; David Salven; Robert M Nissen
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

7.  A complex between DYRK1A and DCAF7 phosphorylates the C-terminal domain of RNA polymerase II to promote myogenesis.

Authors:  Dan Yu; Claudia Cattoglio; Yuhua Xue; Qiang Zhou
Journal:  Nucleic Acids Res       Date:  2019-05-21       Impact factor: 16.971

Review 8.  Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond.

Authors:  Florentin Pastor; Lulzim Shkreta; Benoit Chabot; David Durantel; Anna Salvetti
Journal:  Front Microbiol       Date:  2021-03-29       Impact factor: 5.640

9.  K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.

Authors:  Pengshan Zhang; Zhe Zhang; Yinkun Fu; Ying Zhang; Michael P Washburn; Laurence Florens; Min Wu; Chen Huang; Zhaoyuan Hou; Man Mohan
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

Review 10.  Human Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges.

Authors:  Peng Wang; Esra Karakose; Lauryn Choleva; Kunal Kumar; Robert J DeVita; Adolfo Garcia-Ocaña; Andrew F Stewart
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-16       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.